soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary From the Randomized SELECT Trial

Maintaining adequate hydration while managing GLP-1 side effects requires strategic planning and practical techniques that accommodate reduced appetite and potential nausea

I dont want to be on them forever. Other people have been forced to ration or halt doses because the drugs are costly $1,000 to $1,300 per month and insurance coverage varies or because demand has far outstripped supply, Rothberg noted

Endocrinology 153(3):15381547 Mansoor H, L BA, Morten D, Kathleen D, G EF, R FD et al (2019a) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

So 50 units equals 0.5 mL

Understanding Semaglutide and Its Mechanism for Weight Loss Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to manage type 2 diabetes and aid in weight loss for individuals who are obese or overweight